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Abstract 
In this article, we review current evidence linking immune dysfunction in schizophrenia and 
related psychotic disorders focusing particularly on circulating cytokine, oxidative stress and 
cellular markers of inflammation in various stages on illness from drug naïve first episode 
psychosis to chronic schizophrenia. There is evidence that the acute psychotic episode is 
associated with low-grade systemic inflammation in some patients;  reflected by increased 
concentrations of circulating inflammatory markers in peripheral blood. We discuss evidence 
from general population-based cohort studies reporting an association between inflammatory 
markers and subsequent risk of psychosis, which indicate that inflammation may be a causal 
risk factor for psychosis rather than simply be a consequence of illness. We discuss that an 
immunological understanding of schizophrenia could be clinically useful, as inflammation is 
associated with poor treatment response in first episode psychosis. We briefly present current 
evidence for effectiveness of anti-inflammatory treatment for psychosis, offer suggestions for 
future studies, and highlight notable gaps in current knowledge. 
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Introduction:   
Schizophrenia can be understood as a neurodevelopmental disorder [1, 2], with onset usually 
in early adulthood [3]. Biological research into the pathogenesis of schizophrenia has focused 
on brain structure, function and neurotransmitter abnormalities [4] and genetic risk [5]. 
However, there is also an accepted environmental impact, with a gene and environmental 
(GxE) combined effect related to increased risk, precipitation of illness and/or poorer 
outcomes.  This includes childhood trauma, social and economic deprivation, minority status 
and stressful life events [6]. Increasing evidence suggests a role for the involvement of 
immunological processes in mediating the environmental risk and the pathophysiology at the 
onset and development of schizophrenia. Indeed, schizophrenia has been associated with an 
abnormal activation of the immune system for many years [7-9]. While previous reviews 
have summarised evidence linking schizophrenia with abnormalities in various components 
of the immune system [10, 11], here we focus primarily on circulating cytokine, oxidative 
stress and cellular markers of inflammation. 
 
The immune response is a highly coordinated process involving an array of cell types that 
protect the body from harm while maintaining tolerance to self-antigens and beneficial 
organisms. The first arm is our “innate” defence mechanisms; older in evolutionary terms and 
considered to be a first line defence. Its cellular components include neutrophils, basophils 
and eosinophil’s, monocytes and macrophages, dendritic cells and natural killer (NK) cells, 
which recognise and promote defence against pathogens but lack the sophistication to adapt 
compared to other more recent additions to the immune system [12].  See figure 1. The innate 
humoral component is made up of acute phase proteins such as C Reactive Protein (CRP) and 
the compliment cascade, which allow phagocytic cells to clear pathogens, as well as various 
cytokines (see below). Measurement of CRP as a marker if inflammation is common in other 
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branches of medicine, but with a lack of clinical significance readily apparent is not common 
practice in psychosis.  
 
The second arm of our immune system is the “adaptive” system, which acts on re-exposure to 
a known pathogen, and has the ability to be conditioned. The prime cellular components of 
the adaptive system include T and B lymphocytes. There is considerable “cross-talk” between 
the two major arms of the immune system. T cells comprise key components of the T Helper 
1 (Th1) system and the T Helper 2 system (Th2). The Th1 system is polarised towards the 
production of pro inflammatory (activating) cytokines such as interleukin 2 (IL-2), interferon-
γ (INF-γ), and tumour necrosis factor (TNFα). The Th2 system promotes the generation and 
maintenance of antibody-mediated immune responses as well as production of anti-
inflammatory cytokines such as interleukin- 4 (IL-4), interleukin-10 (IL-10) and interleukin-
13 (IL-13). More recently, a key role for the Th17 system has been discovered, in regulation 
of immune response, so this system is important for pathogenesis of a number of immune-
related disorders [13].    
 
Cytokines are the key signalling molecules that coordinate both innate and adaptive arms of 
the immune system and exert effects in the periphery and the brain. Changes in cytokines 
levels, their receptors and cytokine activity modifiers have been found in the blood and 
cerebrospinal fluid (CSF) of patients with schizophrenia [14]. Previously, the brain was 
thought to be protected from peripheral inflammatory responses; however, it is now clear that 
cytokines and other circulating inflammatory mediators can reach and influence the brain 
using a number of pathways. These pathways include direct entry through leaky 
circumventricular areas in blood-brain barrier (BBB), the lymphatic system as well as 
indirect pathways involving, for example, the Vagus nerve; for a review see [11]. Peripheral 
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or systemic inflammation is therefore relevant for neuropsychiatric disorders such as 
schizophrenia.  
 
Inflammation might exert effects on dopamine via effect on cellular re-uptake and 
glutamatergic transmission and increased production of the tryptophan metabolite quinolinic 
acid, a powerful NMDA receptor agonist. Thus, the relationship of cytokines to known 
neurochemical changes in schizophrenia is of growing interest.  Early changes in 
neurochemicals relevant to schizophrenia, such as glutamate or glutamine may occur in 
individuals with schizophrenia who have deficient defence against inflammatory challenge 
[16]. The effect of inflammation includes the generation of reactive oxygen species such as 
superoxide, hydroxyl and peroxyl. They give rise to oxidative stress, which can damage 
tissues if defense mechanisms are inadequate. Oxidative stress occurs when there is an 
imbalance in the production of free radicals and the body’s ability to counteract this insult via 
the action of antioxidants. Altered antioxidant enzyme response contributes to oxidative 
stress, and is inferred from higher tissue levels of reactive oxygen species (ROS) which leads 
to cell injury or death [15]. NMDA glutamate receptors are downregulated by oxidation [16], 
leading to disinhibition of pyramidal cells and unregulated glutamatergic excess. Thus, it is 
plausible that the response of brain glutamate to inflammation and associated oxidative stress 
will depend on the strength of defences against it. See figure 3. 
 
There are notable difficulties with reported data around markers of inflammation in 
schizophrenia as, for example, studies have used patients in different stages of illness 
progression (prodrome vs. acute vs. chronic illness or active illness vs. remission). Levels of 
inflammatory markers could be also influenced by neuroleptic and other drugs, alcohol and 
illicit drug use, sex, smoking, body mass index (BMI), and co-morbid chronic physical 
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illness. The extensive list of potential confounds may be responsible for some of the 
discrepancies in reported studies [12]. In this chapter, we will review the evidence for 
aberrant circulating cytokines, cellular markers of inflammation and markers of oxidative 
stress in schizophrenia taking into account time and phase of illness, and provide a brief 
overview of CSF changes relevant to these markers. We will also discuss evidence from 
epidemiological cohort studies linking inflammation and psychosis, and the relevance of 
inflammation to treatment response, other risk factors such as early-life adversity, and 
common physical comorbidities for schizophrenia such as coronary heart disease and type-2 
diabetes. 
 
Drug Naïve Psychosis 
Studies of medication naive patients are particularly useful to gain a better understanding of 
inflammatory cytokine alteration in schizophrenia. It is well known that antipsychotic 
medication can influence the immune system. Drzyga and colleagues carried out in vitro 
studies showing that antipsychotic drugs affect immune cell function, which often occurs 
very shortly after initial exposure to drug [17]. However, there are mixed results and differing 
effects, including either stimulatory or inhibitory actions. Relatedly, other recent in vitro 
studies suggest that part of the efficacy of some antipsychotics may be through suppression of 
cytokine mediated microglial activity [18]. For example aripiprazole suppresses apoptosis of 
rodent oligodendrocytes by IFN-γ-activated microglia, and inhibition of TNF-α secretion 
from IFN-γ-activated microglia [19]. Clozapine, the most effective antipsychotic medication, 
influences the immune system. Its effects on white blood cell (WBC) count is well known. 
Roge et al suggest a ‘cytokine storm on initiation’ of clozapine in 50% of patients [20]  with 
longer term effects on IL-6, CRP [21] and high sensitivity CRP (hs-CRP) levels [22].  
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In a systematic review and meta-analysis published in 2014, we included 14 studies that 
together assessed levels of 20 different cytokines and cytokine receptors in 570 neuroleptic 
naive patients. The majority diagnosis was schizophrenia or schizophreniform disorder 
(81%). Highly significant effect sizes emerged for IL-1β, IL-6, sIL2r and TNFα, suggesting 
that an increase in these cytokines in first episode psychosis (FEP) compared with controls, is 
unrelated to medication effects. Non-significant effect size estimates were obtained for IL-2, 
IL-4, and IFN-γ; these cytokines were measured in studies with small samples, and in fewer 
studies altogether, so the analysis were potentially underpowered. However, IL-1β stimulates 
the production of IL-6 and acute phase proteins. sIL-2r flows into the blood during T-cell 
activation and is a common marker for cell mediated immune activation. IL-6 is again pro-
inflammatory; inducing acute phase proteins, and late B-cell differentiation. TNFα we have 
known for some time is a key player in the inflammatory response and induces acute phase 
proteins such as CRP.  
 
Since this review, a small number of studies have explored the medication naive first episode 
group. Notably, Noto et al reported on cytokine profile in 55 FEP patients, showing that the 
presence of co-morbid depression was a significant influence; increased levels of IL-6, IL-10 
and TNFα in FEP patients was found, however FEP patients with depression showed higher 
IL-4 and TNFα levels versus those without depression [23]. 
 
Acute Psychosis 
In a comprehensive meta-analysis published in 2011, Miller et al explored cytokine function 
by phase of illness in schizophrenia. Assessing 40 studies, they found IL-1β, IL-6 and TGF-β 
were raised in the acute phase of illness, both in relapse patients and those with first episode 
psychosis, and reduced with treatment [24]. See figure 2. IL-6 correlated to total level of 
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psychopathology in 2 out of 5 studies [24]. TNF α and IL-6 were the subject of most studies 
(97 and 156 total studies respectively). Thus, there is a proposal that these are state dependant 
markers of inflammation, resolving with symptom reduction. In first episode psychosis, 
Mondelli et al measured BDNF, IL-6 and TNF in 46 patients. Compared to healthy controls 
patients had reduced BDNF gene expression, and increased IL-6 and TNF. A history of 
childhood trauma was associated with lower BDNF mediated through IL-6 [25]. In a more 
recent review, Goldsmith et al investigated acute and chronic cytokine changes in 
schizophrenia, bipolar disorder and depression which included 40 studies on acute 
schizophrenia [26]. In meta-analysis, IL-6, sIL2r, IL-1RA and TNFα were all significantly 
raised in acute schizophrenia, bipolar disorder and depression. There was more heterogeneity 
in FEP samples than acute relapse of established schizophrenia. No publication bias was 
reported for IL-6 [27]. This suggests a lack of specificity of inflammatory pathogenesis of 
psychosis, i.e., the effect of inflammation is trans-diagnostic (see below). As with Noto’s 
paper above [23], the suggestion may be that there is an inflammatory pathway for  a subset 
of psychosis patients, and perhaps those with more affective symptoms. 
 
A recent meta-analysis by Fernandes et al., they consistently found elevated serum levels of 
CRP in both first episode and chronic phase patients, irrespective of medication status [28]. 
Furthermore, an association between CRP levels and positive symptoms but not negative 
symptoms of psychosis was found, suggesting a relation with acute phase of illness. 
However,  Johnsen et al investigated CRP in acute psychosis, finding a particular association 
with cognitive dysfunctions rather than positive symptoms [29]. So overall, findings from 
patient samples on the association of inflammatory cytokines with specific types of 
symptoms is mixed. 
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In terms of markers of oxidative stress, evidence of diminished levels of the anti-oxidant, 
glutathione (GSH) [30, 31] has been reported. GSH is an antioxidant which provides within 
cell protection, and when depleted contributes to oxidative stress. Flatlow, Buckly and Miller 
reported a decrease in GSH in acutely relapsed patients with schizophrenia together with 
other anti-oxidants such as superoxide dismutase (SOD) and catalase (CAT), however there 
was significant heterogeneity in reported studies such that SOD and CAT but not GSH was 
reduced in FEP[32]. This may suggest a more persevered oxidative defense earlier in the 
course of illness. 
 
As a substantial minority of patients with FEP do not go on to develop an enduring mental 
illness, and it may be that those with a protective oxidative defense to cellular stress have 
better outcomes [33]. This remains to be tested, however Wang et al investigated Cysteine, a 
semi-essential amino acid and a precursor of GSH glutathione, as a potential indicator of 
preserved cognitive function in FEP with some positive findings [34]. The functional 
consequences of increased oxidative stress or reduced defence against this oxidative stress in 
the brain are still to be fully understood. However, it is likely that changes in neuronal 
membrane permeability eventually causing cell death is a mechanism of effect which may 
lead to grey matter volume (GMV) loss [35]. In respect to neurochemical change known in 
psychosis, Berk et al (2008) described the process of oxidative stress resulting in over 
activation of NMDA and altered dopamine receptor function.  Whilst schizophrenia is no 
longer understood within a simplistic conclusion of hyperdopaminergia, rather consisting of 
regionally specific prefrontal hypodopaminergia and subcortical hyperdopaminergia, the 
cumulative effect of over active or more readily available dopamine may account for positive 
symptoms [36].  NMDA glutamate receptors are downregulated by oxidation leading to 
disinhibition of pyramidal cells and unregulated glutamatergic excess [16].  
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 Chronic Schizophrenia 
TNFα, IL-12, INF-γ and sIL2r group have been reported to be elevated in both acute illness 
and stable ‘outpatients’ with chronic schizophrenia. Goldsmith et al found that contrary to 
acute phases of illness there was more specificity to diagnostic groups: in chronically ill 
patients, the levels of IL-6 were significantly increased in schizophrenia, euthymic (but not 
depressed) bipolar disorder and major depressive disorder (MDD) compared with controls 
[26]. IL-1β and sIL2R were significantly increased in chronic schizophrenia and euthymic 
bipolar disorder. TNFα has consistently been reported as a trait marker of neuroinflammation 
[27]. Goldsmith et al review confirmed evidence that TNF was raised in acute schizophrenia 
compared to controls and remained so after treatment; thus as a trait marker of inflammation. 
 
In meta-analysis of 5 studies, Miller and Culpeper found that 28% of patients with chronic 
schizophrenia have an elevated CRP [37]. In a recent study of 295 patients with 
schizophrenia and 192 with bipolar disorder, CRP was elevated in the schizophrenia even 
after adjusting for age, gender, race, maternal education, smoking status, and BMI but this 
was not found in bipolar disorder [38]. The association between CRP levels and cognitive 
functioning in patients with predominantly chronic schizophrenia has been reported in one 
cross-sectional study [39]. Together these studies suggest a poorer cognitive deficit course 
may be associated with enduring neuroinflammation. 
 
There is substantial evidence of impaired oxidative defense in chronic schizophrenia, as 
reviewed by Flatlow et al in 2013 [32]. Negative symptoms have been associated with low 
levels of GSH, and positive symptoms have been positively correlated with SOD activity. A 
study by Fraguas et al assessed the relationship between GMV and GSH in the brains of 
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patients with schizophrenia, with a progressive decline in GMV correlated to declining 
circulating GSH [40]. Thus, the deficit state of some patients with schizophrenia may be 
related to a specific lack of defence against oxidative stress. 
 
 We have also previously reported significant clinical and phenomenological commonality 
between schizophrenia and depression [41]. In schizophrenia the dysfunction of glutamate is 
substantial: with clear evidence for Glx abnormality in brain areas such as the posterior 
medial prefrontal cortex (pmPFC). Increased Glx is seen in younger patients or more acute 
phases of illness, whereas reduced Glx has been reported in patients who are older and have 
residual negative symptoms [42]. Just as in schizophrenia, there is substantial evidence for 
increase in peripheral markers of inflammation in MDD. In schizophrenia, it may be that the 
presence of depression is a key component explaining the cytokine imbalance responsible for 
the immune-inflammatory abnormalities described. However there is also evidence that 
immune dysfunction is present in samples of patients with schizophrenia even when 
depression is excluded or controlled for [43]. Thus models may include duel pathways for 
psychosis and depression, both of which have dysfunctional immune profiles, or that the 
presence of both has greater impact than the sum of each individually. The poorer outcome, 
increased risk of relapse, quality of life and functional outcome for those patients with both 
depression and schizophrenia may speak to the latter possibility [44]. Early changes in 
neurochemicals such as Glx may result in more significant impact for those individuals with 
deficient defence against this inflammatory challenge [16. The effect of inflammation 
includes the generation of reactive oxygen species such as superoxide, hydroxyl and peroxyl. 
The substantial evidence of impaired oxidative defense in early psychosis with diminished 
levels of GSH [30, 31, 45] show that the response of brain glutamate to inflammation and 
associated oxidative stress will also depend on the strength of defences against it. Thus 
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clinically poorer outcomes, such as seen with some subjects with depression and 
schizophrenia may be related not just to the effect of chronic inflammation but also impaired 
defence against this. 
 
 
 
 
 
Longitudinal studies 
Psychological stress can active innate immune response [46], so cytokine elevation during 
acute psychosis could be a consequence of illness rather than be its cause. Longitudinal 
studies are need to establish, or refute, a potentially causal role of inflammation in the 
pathogenesis of psychosis. Evidence from population-based longitudinal cohort studies from 
the UK, Finland and Sweden has linked higher levels of IL-6, CRP and Erythrocyte 
Sedimentation Rate (ESR) in childhood/adolescence with risk of psychotic symptoms or 
diagnosis of schizophrenia subsequently in adulthood [47-49]. Using data from the Avon 
Longitudinal Study of Parents and Children (ALSPAC), a general population birth cohort, we 
have reported that higher levels of IL-6 in childhood is associated with increased risk of 
psychotic symptoms at early adulthood in a linear dose-response fashion [47]. See Figure X. 
Evidence for this association remained after controlling for sex, BMI, social class, ethnicity 
and childhood psychological and behavioural problems preceding the measurement of IL-6. 
Although in ALSPAC, CRP was not associated with psychosis risk, in the Northern Finland 
Birth Cohort 1986 (NFBC 1986) higher levels of CRP in adolescence was associated with 
increased risk of hospitalisation with a diagnosis of schizophrenia subsequently in adulthood. 
Furthermore, there was evidence that higher CRP levels in adolescence was associated with 
Comment [GK1]: I will add a Figure 
here 
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earlier age at illness onset [49]. These findings are consistent with a Danish study reporting 
that higher CRP at baseline is associated with increased risk of late- and very-late-onset 
schizophrenia subsequently at follow-up [50]. More recently a longitudinal study based on 
Swedish male conscripts reported that higher ESR, a marker of systemic inflammation, in 
early-adulthood is associated with increased risk of schizophrenia subsequently in adulthood 
[48]. Together these studies suggest that reverse causality is an unlikely explanation for 
previously observed association between inflammatory markers and psychosis. Inflammation 
could be a cause for psychosis rather than simply being a consequence of illness.   
Although previous longitudinal studies have controlled for key confounders such as sex, 
BMI, social class, residual confounding still might explain the association between 
inflammatory markers and psychosis. Recently, we have used genetic association analysis 
informed by Mendelian randomization (MR) which indicates that residual confounding is 
unlikely to explain the association between IL-6 and psychosis fully. MR is based on the idea 
that if a biomarker is causally related to an illness, genetic variant(s) regulating levels/activity 
of that biomarker should also be associated with the illness [51]. Using data from the 
ALSPAC birth cohort, we have shown that a genetic variant in the IL-6 receptor gene (IL6R 
Asp358Ala; rs2228145) that is known to dampen down inflammation by impairing the 
activity of IL-6 is protective for severe depression and/or psychosis [52]. The genetic variant 
is strongly associated with serum IL-6 and CRP levels, but not with any common 
confounders of the inflammation-psychosis relationship such as sex, social class, ethnicity, 
and body mass. Genetic variants segregate at random during meiosis and are unrelated to 
sociodemographic and other confounders. Therefore, an association between psychosis and a 
genetic variant that regulates IL-6 activity strongly indicates that the IL-6/IL-6R pathways are 
causally linked to psychosis. 
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Cerebrospinal fluid (CSF) studies 
Meta-analysis of studies of CSF from patients with schizophrenia suggests that levels of 
inflammatory cytokines are increased in patients with psychosis. A meta-analysis of 16 
studies published in 2018 by Wang et al reported that CSF levels of IL-1β, IL-6 and IL-8 
were significantly elevated in schizophrenia patients compared with controls [53]. Similar 
findings were also observed for depression. Whether levels of inflammatory markers in 
peripheral blood corresponds with neuroinflammaton is an important question. This meta-
analysis also reported that many CSF alterations are also concordant with those in the 
peripheral blood, particularly for schizophrenia [53]. This provides some validity to the use 
of peripheral markers of inflammation in schizophrenia research. This finding is consistent 
with a study by Coughlin et al that measured IL-6 in the CSF of patients with recent onset 
schizophrenia also undergoing a positron emission tomography (PET) study of translocator 
protein 18k Da (TSPO), a marker of microglial activation using [11C] DPA-713[54]. Whilst 
non-significant results were seen in the TSPO analysis, IL-6 levels was significantly raised 
in patients compared to controls. Furthermore, the study found IL-6 levels in the CSF 
correlated significantly with circulating IL-6. 
 
Trans-diagnostic effect of inflammation 
Studies of inflammatory markers in peripheral blood and CSF suggest that inflammation is 
associated with a number of psychiatric disorders including schizophrenia and related 
psychoses [10, 14, 53, 55, 56], depression [57, 58], anxiety [59], post-traumatic stress 
disorder (PTSD) [60], autism [61], Alzheimer’s disease and other dementias [62]. However, 
possible reasons for this apparent trans-diagnostic association of inflammation are unknown. 
We have recently reported that the apparent trans-diagnostic effect may arise from 
association of inflammation with symptoms that are commonly shared between disorders 
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[63]. Using a symptom-level data on 10 positive and 10 negative symptoms of psychosis 
assessed in adolescent participants from the from the ALSPAC birth cohort, we have shown 
at the at group level positive and negative symptom dimension scores were associated with 
serum CRP levels in a similar fashion. At individual symptom level, CRP was associated 
with particularly auditory hallucinations and anhedonia. Auditory hallucinations can occur in 
psychosis, depression and anxiety disorders [64]. Anhedonia is both an important negative 
symptom for psychosis and a core feature of depression [64].  
Association between inflammation and anhedonia is supported by experimental studies. In 
non-human primates, chronic, low-dose peripheral interferon administration reduces striatal 
dopamine release in association with anhedonia-like behaviour [65]. In healthy volunteers, 
inflammation induces hedonic alterations (decreased preference for reward and increased 
avoidance of punishment) [66], which resemble anhedonia. Other reasons for this apparent 
trans-diagnostic effect could be shared genes that contributes to inflammation and risk of 
depression and schizophrenia. Genetic overlap between schizophrenia, bipolar disorder and 
depression is well established.  
 
Shared risk factors, particularly early-life adversity, could be another explanation for the 
apparent trans-diagnostic effect of inflammation. Childhood abuse/maltreatment may 
program the immune system leading with increased concentrations inflammatory markers in 
adulthood [67], which in turn, may increase psychiatric risk. In the ALSPAC birth cohort, 
maternal parental depression is associated with higher levels of IL-6 and CRP in childhood 
and with higher risk of depression and psychosis in early-adulthood in offspring [68]. 
Furthermore, childhood IL-6 levels mediate the association between prenatal depression and 
offspring psychosis risk. These findings are consistent with the developmental programming 
hypothesis by David Barker, which posits that exposure to stress during critical period of 
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development may program certain physiological system(s) leading to increased risk of 
chronic illnesses of adult life [69]. Early-life adversity is associated with coronary heart 
disease, type-two diabetes, which are common co-morbidities for schizophrenia and 
depression. Young adults with psychotic symptoms display evidence of dysglycaemia, which 
is linked with levels of IL-6 in childhood [70]. Therefore, whether programming of innate 
immune response by early-life adversity may explain the comorbidity between schizophrenia, 
depression, coronary heart disease and type-two diabetes is an interesting hypothesis that 
needs investigating. 
 
Association with treatment response and novel therapeutic options 
Mondelli et al have reported an association between innate immune activation and poorer 
treatment response in 57 patients with FEP: non-responders (as defined by an absence of 
clinically significant symptom response in keep in with remission criteria at 12 weeks) had a 
significantly higher IL-6 and INF-γ at baseline. They also reported an aberrant cortisol 
wakening response and suggest this combination of markers may be an early signal of poor 
outcome [71]. Indeed, inflammatory mechanisms, as outlined above, have been cited as one 
of the potential mechanism of effect of Clozapine in treatment resistant schizophrenia.  
 
As well as poor treatment response, makers of inflammation may indicate poorer physical 
health outcomes: Russell et al investigated 53 FEP patients and showed that FEP patients 
with raised CRP were at more risk of developing short-term metabolic abnormalities 
including dyslipidemia, independent of weight-gain [72]. As mentioned earlier, in the 
ALSPAC birth cohort young adults with psychotic symptoms displayed evidence of 
dysglycasemia which was associated with childhood IL-6 levels [70]. Thus, the potential for 
stratifying treatment approach; early targeting of potential treatment resistance or heightened 
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monitoring from adverse effects of antipsychotics shows some promise in a personalized 
approach to FEP and schizophrenia.  
 
Because inflammation is associated with BMI, smoking, alcohol use, physical comorbidity, 
antipsychotic treatment and treatment induced weight gain, further work is needed to 
understand whether and how measuring inflammation in clinical setting could be useful for 
predicting response to antidepressant/ antipsychotic treatment, and for identifying patients 
who are likely to benefit from immunomodulatory treatments. Inflammation is unlikely to be 
relevant for illness pathogenesis in all patients with psychosis. Clinical trials indicate anti-
inflammatory drugs may be helpful for patients with depression who show evidence of 
inflammation [73, 74]. However results are mixed: as demonstrated by the recent large 
negative BeneMin trial [75] and therefore, patients with psychosis who do show evidence of 
inflammation may be more suitable candidate for RCTs of anti-inflammatory drugs in future.  
 
Conclusion and future research 
See key findings and challenges box below. For a number of years now there have 
considerable efforts to have a better understanding of the immunological and inflammatory 
aspects of schizophrenia, in the hope that this might lead to might lead to novel approaches to 
diagnosis and treatment. Some aspects are becoming clearer: there is good evidence of 
longitudinal association of inflammatory markers with psychosis prior to the onset of clinical 
disorder; elevated makers of inflammation and reduced oxidative stress in medication naive 
and first episode subjects. Evidence for treatment response prediction of outcome is also 
promising. However, there remain significant challenges: the heterogeneity of studies pulled 
into meta-analysis, a lack of replication in a number of studies and a significant heterogeneity 
of results with other major mental disorders. This may speak to a lack of specificity of the 
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inflammatory makers; a signal of any major brain illness, or to the lack of specificity in 
diagnostic groups. Indeed, the Kraepelinian dichotomy is challenged on many fronts; yet 
often remains set within biological research. Therefore, shifting the focus of research from 
syndrome to symptom (or constellation of symptoms) may help to elucidate the role of 
inflammation more fully. The use of the research domain criteria (RDoC) could lead to a 
better understanding of the mechanisms of psychopathology; as demonstrated the effects of 
inflammation are likely to cut-across traditional diagnostic categories. This framework would 
allow examining how inflammation influences developmental trajectories of 
neuropsychiatric symptoms, cognition or functional outcome over the life course.  
 
An ambition would be phenotyping of patients based on their immunological characteristics, 
prior to choosing a tailored treatment approach including antipsychotic, anti-inflammatory 
and other novel neuroprotective medication  and the length of monitoring and psychological 
interventions needed in those at most risk of cognitive decline or negative symptoms.  Thus, 
if a subset of severe mental illness is characterised by and inflammatory profile, then anti-
inflammatory agents may be more effective if targeted specifically to these patients. Presently 
Celecoxib has the strongest evidence base for interventions[76]; this may be larger still if 
tailored to those with active inflammatory pathway. 
 
Many of the major advances in our understanding of the pathophysiology of schizophrenia 
suggest immune dysfunction as a novel and promising finding. The potential for translation in 
to treatment advances may be within our grasp. Our understanding of both the nosological 
boundaries and “end phenotypes” of psychotic disorders advances, and this together with our 
increasing knowledge of the complexities of the cellular and humoral immune system and its 
genetic coding, provide major advances in our understanding of neurobiological process in 
18 
 
psychotic illness. The investigation of immune dysfunction in psychosis offers the greatest 
potential to advance our understanding of schizophrenia in the 21st century. 
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 Key Findings  
• Consistent evidence suggests patients with schizophrenia have elevated peripheral 
markers of inflammation 
• Peripheral markers of inflammation appear to pre-date the onset of illness and be 
independent to medication. 
• Depression and Schizophrenia both have elevated pro-inflammatory profiles: 
understanding the co-morbidity in psychosis is important. 
• Physical health outcomes may be poorer in those with psychosis and immune 
dysfunction 
 
Key Gaps 
• Future research should elucidate further the relationship between peripheral markers 
of inflammation and structural or functional brain changes 
• It remains unclear whether inflammation may be an effective target for novel 
therapies: anti-inflammatory and repurposed medication trials have produced mixed 
results 
• A key question remains as to whether it is possible to stratify or better target those 
patients with psychosis and immune dysfunction. 
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 Figure 1 Cytokine profile in medication naive first episode psychosis: Modified from 
Upthegrove et al  2014 (14). Increased IL-6, TNF-α, IL-1β and sIL-2r 
 
  
STUDY Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper Relative R  
g error Variance limit limit Z-Value p-Value weight
IL-1B DiNicola 2012 1.326 0.509 0.259 0.329 2.323 2.608 0.009 6.45
IL-1BSong 2009 1.039 0.175 0.031 0.695 1.383 5.919 0.000 54.13
IL-1 B Theodoropoulou 2001.335 0.206 0.042 0.932 1.739 6.494 0.000 39.42
1.174 0.129 0.017 0.921 1.427 9.095 0.000
-2.00 -1.00 0.00 1.00 2.00
  
 
STUDY Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper Relative R  
g error Variance limit limit Z-Value p-Value weight
TNFa Di Nicola 2012 0.896 0.492 0.242 -0.068 1.861 1.821 0.069 6.54
TNFa Song 2009 0.808 0.171 0.029 0.472 1.144 4.717 0.000 53.98
TNFa Theo 2001 1.137 0.200 0.040 0.744 1.529 5.672 0.000 39.47
0.944 0.126 0.016 0.697 1.190 7.495 0.000
-2.00 -1.00 0.00 1.00 2.00
  
 STUDY Statistics for each study Hedges's g and 95% CIHedges's Standard Lower Upper Relative R  
g error Variance limit limit Z-Value p-Value weight
IL-6 Di Nicola 2012 0.959 0.494 0.244 -0.009 1.928 1.941 0.052 19.51
IL-6 Akliyama 1999 0.923 0.339 0.115 0.259 1.586 2.725 0.006 20.15
IL-6 Borovcain 2012 0.830 0.204 0.041 0.431 1.229 4.079 0.000 20.53
IL-6 Fernandez –Ega 20090.524 0.202 0.041 0.129 0.920 2.597 0.009 20.54
IL-6 Ganuili  1989 8.067 0.541 0.293 7.006 9.128 14.903 0.000 19.28
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 STUDY Statistics for each study Hedges's g and 95% CIHedges's Standard Lower Upper Relative R  g error Variance limit limit Z-Value p-Value weight w
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Figure2: From Upthegrove and Barnes 2015 
 
 
 
Figure 3:Depression, psychosis, inflammation and oxidative defence Title needed 
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